The
cystic fibrosis market had a market value of more than USD 695 million in 2012
and is anticipated to rise drastically over the future period in the major 8
developed countries and will reach more than USD 4.0 billion by 2019. Thus
associates to compound annual growth rate of more than 30%.
Original
treatment with disease-modifying mechanism of action is the main feature
increasing the growth of the market in terms of value. The constructive effect
of the market’s new applicant will counteract the effects of major patent
failures throughout the estimated period.
Read Complete Report With TOC @
http://www.radiantinsights.com/research/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth
The
first ever cystic fibrosis therapy was CFTR (Cystic Fibrosis Transmembrane
conductance Regulator) for treating the root reasons of the illness instead of
the symptom. This resulted into the Patients’ enhanced help and value of life.
Among CFTR modulator, Kalydeco was the first one to reach the market. This was
in the market since 2012. It could treat only a tiny part of CF people, yet the
market value had a major effect of it.
With the market entry of Ataluren &
lumacaftor, the effect is going to be repetitive on a huge extent, because of
the ability of it being used on a bigger number of the CF sufferers.
Llumacaftor, Kalydeco, and early previous phase CFTR modulator are developed by
Vertex Pharmaceuticals Inc. These are hence anticipated to be performing a
major role in developing the forth coming market.
Download sample Copy of This Report
at: www.radiantinsights.com/research/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth#tabs-4
The
rates of the Cystic Fibrosis Transmembrane conductance Regulators are expected
to be high owing to the effects that are represented on the disease
modification and benefits for the clinics. Suggestive therapies are going to be
used in CFTR modulator combination, and yet it will be an essential part for
the plan of the CF treatment. Particularly, the antibiotic sector is
anticipated to turn out to be ready for action and filled to capacity in the
future period. This will be because of the fresh market applicants challenging
for the share of the market, low in price, and products of standard tobramycin.
Table of Contents
Table
of Contents 4
1.1
List of Tables 5
1.2
List of Figures 6
2
Introduction 7
2.1
Disease Introduction 7
2.2
Symptoms 8
2.3
Etiology 8
2.4
Pathophysiology 9
2.5
Diagnosis 9
2.6
Prognosis 10
2.7
Assessment of Disease Severity 10
2.8
Treatment 10
See More Reports of This Category
by Radiant Insights:
·
Australia Airway and Anesthesia Devices Market
Outlook to 2021 - http://www.radiantinsights.com/research/australia-airway-and-anesthesia-devices-market-outlook-to-2021
·
India Airway and Anesthesia Devices Market Outlook
to 2021 - http://www.radiantinsights.com/research/india-airway-and-anesthesia-devices-market-outlook-to-2021
3 Marketed Products 12
3.1
Overview 12
3.2
Product Profiles 13
3.2.1
Pulmozyme (dornase alfa) - Genentech 13
3.2.2
Bronchitol (mannitol) - Pharmaxis 14
3.2.3
TOBI (tobramycin) - Novartis 15
3.2.4
TOBI Podhaler (tobramycin) - Novartis 16
About Radiant Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and individuals
procure market research reports, helping them in the decision making process.
We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports,
our experienced research coordinators also offer a host of ancillary services
such as, research partnerships/ tie-ups and customized research solutions.
For More Information, Visit Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.radiantinsightsinc.blogspot.com
No comments:
Post a Comment